SureTrader Advertisement SureTrader
Home > Boards > US OTC > Biotechs >

Amarantus Bioscience Holdings Inc. (AMBS)

AMBS RSS Feed
Add AMBS Price Alert      Hide Sticky   Hide Intro
Moderator: YankeeDolphin, 1~Eye~Jack!!, zoomboom, JJAAMMAANN, Rosym, $tock~$crooge!!
Search This Board:
Last Post: 5/2/2016 6:58:49 PM - Followers: 735 - Board type: Free - Posts Today: 0

 

(AMBS) Amarantus BioScience Holdings, Inc. 

Amarantus is a biotechnology company developing treatments and diagnostics for diseases associated with neurodegeneration and protein misfolding-related apoptosis.
The company has licensed Eltoprazine, a Phase 2 ready Parkinsons Levadopa induced Dyskinesia.

The company has an exclusive worldwide license to the Lymphocyte Proliferation test ("LymPro Test®") is a
 diagnostic blood test for Alzheimer’s disease and is being evaluated as a diagnostic blood test for Traumatic Brain injury and Chronic Traumatic Encephalopathy.  (MANF) is a human growth factor that plays a key role in the prevention of apoptosis (cell death). It is being developed for the potential treatment of RP, Parkinson's disease, Wolfram syndrome, diabetes, Alzheimer's disease and traumatic brain injury.
Amarantus is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders.
The Company also owns intellectual property rights for the diagnosis of Parkinson's Disease ("NuroPro") and the discovery of neurotrophic facotrs ("PhenoGuard").

ESS, previously known as PermaDerm®  is being developed to be the only tissue-engineered skin prepared from autologous (patient's own) skin cells consisting of both epidermal and dermal layers. A small harvested section of the patient's own skin can be grown to graft an area one hundred times its size in as little as thirty days. 

MSPrecise is a groundbreaking advancement for the diagnosis of multiple sclerosis and is anticipated to play a pivotal role given the current high rate of misdiagnosis
MSPrecise is a lab-developed test. 
For further information, please visit www.Amarantus.com, or connect with the company in FacebookTwitter, LinkedIn & Google+

 

 
                                                                                      
 


 

NEWS



Bio-engineering skin to treat severe burns
 
 

   Videos

 

Gerald Commissiong, CEO of Amarantus BioScience Holdings, Inc. (OTCQX: AMBS) chats with Bob Power, OTC Markets VP of Corporate Services
Mar. 18, 2016

 
SNNLive with Amarantus Bioscience Holdings, Inc. (OTCQX: AMBS)  
December 2015


 

ESS Patients: Dr. Ahrenholz Interview Part 1 
 

ESS vs the Competition: Dr. Ahrenholz Interview Part 2

The Need for ESS: Dr. Ahrenholz Interview Part 3
 

 Predicting Alzheimer's before it      starts Published on Apr. 8, 2015
 SNNLive - Amarantus BioScience
Holdings, Inc. - 
Dec. 12, 2014

Developing an Accurate Test for Multiple Sclerosis - Mar. 5, 2014
 
 
                                                                                                                  
 
 
    
       
 


                                                               Contact Information

Amarantus BioScience Holdings, Inc.
655 Montgomery Street
Suite 900
San Francisco, CA 94111

 

c/o ICS Corporate Services SA
29 quai du Mont Blanc
CH-1201 Geneva
Switzerland












 

info@amarantus.com
pr@amarantus.com


Phone: (415) 688-4484
Fax: (408) 852-4427


Gerald's email address
Gerald@amarantus.com



IR Calendar 






 

INVESTOR RELATIONS

Jenene Thomas Communications
Jenene Thomas
T: 908-938-1475

ir@amarantus.com


 

TRANSFER AGENT

VStock Transfer, LLC
Allison Niccols
77 Spruce Street
Suite 201
Cedarhurst, N 11516
T: 212-828-8436
F: 646-536-3179
info@vstocktransfer.com
www.VStockTransfer.com

 

 
Throughout my 50+ years in the biopharmaceutical industry, I have seen many programs with great promise, but very few programs that possess the fundamentally groundbreaking scientific potential to modify disease biology inherent in MANF This vast potential for MANF is what makes today’s announcement personally so exciting for me, as the initiation of IND-enabling studies (which start with initiation of clinical grade manufacturing) has been the rate-limiting step for true product development value creation for MANF not only for the ophthalmology programs, but also the rest of the MANF pipeline.
 
  Dr. Wen commented, "We continue to see very encouraging preclinical data with MANF. I am looking forward to continue further development of MANF in collaboration with Amarantus, as I believe it has the potential to address RP, as well as other ophthalmologic disorders with serious unmet need and improve the quality of life of patients where no viable treatments exist today."
More information
         “We are very pleased with the data generated in RP from Dr. Wen’s lab at University of Miami’s Bascom Palmer Eye Institute, one of the world’s most prestigious ophthalmology research and treatment centers,” said Gerald E. Commissiong, President & CEO of Amarantus BioScience Holdings, Inc. “Given the recent granting of orphan drug designations in both the US and EU, the presentation of this data is very timely as we build momentum for MANF in this devastating orphan indication, as well as continue to further establish the MANF orphan ophthalmology franchise.

   Amarantus Receives Orphan Drug Designation for MANF From U.S. Food and Drug Administration for Treatment of Retinitis Pigmentosa
 "We are very pleased to receive orphan drug designation for MANF in RP. This represents an important milestone for the company as well as a significant step forward for our clinical and regulatory strategy," said Gerald E. Commissiong
 Most people with RP are legally blind by age 40. It is estimated that the market opportunity for Retinitis Pigmentosa exceeds $10B annually.
 
                                                                            

 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
AMBS
Current Price
Volume:
Bid Ask Day's Range
Wiki
SureTrader
AMBS News: Current Report Filing (8-k) 04/21/2016 04:21:56 PM
AMBS News: Notification That Annual Report Will Be Submitted Late (nt 10-k) 03/30/2016 05:40:56 PM
AMBS News: Proxy Soliciting Materials (revised) (prer14a) 03/14/2016 05:30:37 PM
AMBS News: Current Report Filing (8-k) 03/07/2016 05:02:44 PM
AMBS News: Current Report Filing (8-k) 03/04/2016 05:28:32 PM
PostSubject
#123648  Sticky Note AMBS...BIG BOOM...When the Door Closes... JJAAMMAANN 03/09/16 02:22:12 PM
#124659   Agenda on April 30 newflow 05/02/16 12:28:48 PM
#124658   I believe this a big event and i newflow 05/02/16 12:23:32 PM
#124657   Vatican Speaker David H. Ahrenholz, MD, FACS newflow 05/02/16 12:19:34 PM
#124656   I'm sorry for many small investors like me Bachbla 05/02/16 11:53:55 AM
#124655   not so sure. el_lobodewallst 05/02/16 07:37:43 AM
#124654   or they may just dig themselves deeper... JPetroInc 05/01/16 03:04:37 PM
#124653   IMHO - voting rights assigned to the 3 JPetroInc 05/01/16 02:57:10 PM
#124652   JP company doesn't care, as long as Gerald Inoviorulez 04/30/16 10:14:35 PM
#124651   Had management stuck to the original plan of Inoviorulez 04/30/16 10:11:55 PM
#124650   AMBS signed a Registration Rights Agreement on 4/14/16 JPetroInc 04/29/16 08:47:27 PM
#124649   Enjoy your 12,000 a week Week salery lavish Bachbla 04/29/16 04:58:00 PM
#124647   Sold from .08 to 8 bucks to 10 Bachbla 04/29/16 04:49:20 PM
#124642   400% MORE Dilution COMING 21ZNA9 04/29/16 03:52:41 PM
#124641   how does Gerald expect to "build shareholder value" JPetroInc 04/29/16 03:28:01 PM
#124640   that was all done prior to the RS JPetroInc 04/29/16 01:25:46 PM
#124637   Too funny shamalam 04/29/16 06:49:13 AM
#124636   APB just released JPetroInc 04/28/16 08:28:25 PM
#124635   450k shares dumped JPetroInc 04/28/16 08:06:34 PM
#124634   $AMBS Daily and Weekly Ichimoku Chart http://s $Pistol Pete$ 04/27/16 03:07:51 PM
#124632   here you go... JPetroInc 04/27/16 06:52:56 AM
#124631   That's why GC left this stage, keeps his sante1 04/26/16 11:16:31 PM
#124629   great post der_deutschetrader 04/26/16 09:37:19 AM
#124628   you neglected to mention the hundreds of thousands der_deutschetrader 04/26/16 08:26:09 AM
#124627   Baggage claim carousel #5 Thank you for flying ambs shamalam 04/25/16 07:44:32 PM
#124625   AMBS-Let's do it!! YankeeDolphin 04/25/16 01:51:23 PM
#124623   I want this to be made clear, We Shadowfaxin 04/25/16 08:39:20 AM
#124622   LymPro's Marketing Plan JPetroInc 04/25/16 07:02:17 AM
#124621   then Rubinfeld must have also know that AMBS JPetroInc 04/25/16 06:46:04 AM
#124620   He never saw that the CEO would switch GoClippers 04/24/16 08:47:55 PM
#124619   Because when Rubenfield signed on board he thought Inoviorulez 04/24/16 08:41:37 PM
#124617   That is a possibility. But what is the Coolstocks 04/24/16 06:29:39 PM
#124616   do you think Gerald wakes up every single JPetroInc 04/24/16 04:25:16 PM
#124615   good for you man. I don't blame you, Inoviorulez 04/24/16 11:46:12 AM
#124613   Yes but you can't really blame Dr. Rubenfield, Inoviorulez 04/24/16 10:56:37 AM
#124612   JP I love your facts, and I hope Inoviorulez 04/24/16 10:53:25 AM
#124611   No NuroPro Revenue JPetroInc 04/24/16 09:26:59 AM
#124610   BC SeraPro Question 7/10/14: “Suggestions publish data in JPetroInc 04/24/16 09:17:00 AM
#124609   "We will Up List from Strength" JPetroInc 04/23/16 08:30:23 PM
#124608   I agree.I was wondering about his statements about newflow 04/23/16 07:11:57 PM
#124607   the CEO is quoted as building "Shareholder Value" JPetroInc 04/23/16 06:45:02 PM
#124606   It seems you are a new investor here. Coolstocks 04/23/16 05:12:24 PM
#124605   Its a biotech company with on going R&D.Where newflow 04/23/16 01:23:40 PM
#124604   If there ever was a group of people SidVicious 04/23/16 12:43:34 PM
#124603   so they give the majority of voting rights JPetroInc 04/23/16 12:30:01 PM
#124602   You are correct anything "might" happen including the Ragnaroc 04/22/16 09:40:36 PM
#124601   Another RS in the near future? AMBS is JMTX 04/22/16 06:30:10 PM
#124600   Keep punching man... that is all you can DukeNukem 04/22/16 06:28:12 PM
#124599   Yes but most likely to occur since they IPO$ 04/22/16 06:02:21 PM
#124598   Come on, that's still speculation myersvodka 04/22/16 06:01:45 PM
#124597   This might happen after shareholders approval in June.Any newflow 04/22/16 05:59:29 PM
PostSubject